Literature DB >> 15456543

Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells.

Hai-lin Liu1, Li Huo, Lei Wang.   

Abstract

AIM: To study the effect of octreotide on cell proliferation and apoptosis in different hepatocellular carcinoma (HCC) cells and hepatocytes.
METHODS: The proliferation of HCC cells (HepG2, SMMC-7721) and hepatocytes (L-02) was determined by MTT assay. Apoptosis was detected either by fluorescent staining, transmission electron microscopy or flow cytometry. The content of AFP in the supernatant of cultured HCC cells was determined by electrochemiluminescence immunoassay. The expression of SSTR subtypes was identified by RT-PCR.
RESULTS: The proliferation of HCC cells and L-02 cells was inhibited significantly by octreotide (0.25, 0.5, 1.0, 2.0 and 4.0 mg/L). However, the apoptosis of HCC cells markedly increased in a concentration-dependent manner. Both the apoptosis index and the percentage of apoptotic cells in L-02 cells were significantly lower than those of HepG2 and SMMC-7721 cells. The content of AFP in the supernatant of cultured HepG2 cells treated with octreotide was also statistically reduced. Furthermore, SSTR2 and SSTR4 were positive in both the hepatocellular carcinoma cells and in the L-02 cells. SSTR3 was only expressed in the two heptatocellular carcinoma cells, and SSTR5 was found in the SMMC-7721 cells. No SSTR1 was detected either in HCC cells or L-02 cells.
CONCLUSIONS: Apoptosis induction is a major mechanism of octreotide inhibition on hepatocellular cells. SSTR3 is expressed in the HCC cells, but not in the L-02 cells, which suggests a molecular basis for the HCC-selective effects of octreotide. Copyright 2004 Acta Pharmacologica Sinica

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15456543

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  19 in total

1.  The effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinoma.

Authors:  N M Abdel-Hamid; O M Mohafez; M H Nazmy; A Farhan; K Thabet
Journal:  Environ Health Prev Med       Date:  2015-03-01       Impact factor: 3.674

2.  Pharmacokinetic and pharmacodynamic evidence for developing an oral formulation of octreotide against gastric mucosal injury.

Authors:  Xi-Nuo Li; Tai Rao; Yang-Fan Xu; Kang-Rui Hu; Zhang-Pei Zhu; Hao-Feng Li; Dian Kang; Yu-Hao Shao; Bo-Yu Shen; Xiao-Xi Yin; Lin Xie; Guang-Ji Wang; Yan Liang
Journal:  Acta Pharmacol Sin       Date:  2017-11-30       Impact factor: 6.150

3.  Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells.

Authors:  Nikos J Tsagarakis; Ioannis Drygiannakis; Antonis G Batistakis; George Kolios; Elias A Kouroumalis
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

4.  Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.

Authors:  Katharina Hopp; Cynthia J Hommerding; Xiaofang Wang; Hong Ye; Peter C Harris; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 10.121

Review 5.  Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken.

Authors:  Dimitrios N Samonakis; George Notas; Nikolaos Christodoulakis; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2008-02-14       Impact factor: 3.199

Review 6.  Current systemic treatment of hepatocellular carcinoma: A review of the literature.

Authors:  Kai-Wen Chen; Tzu-Ming Ou; Chin-Wen Hsu; Chi-Ting Horng; Ching-Chang Lee; Yuh-Yuan Tsai; Chi-Chang Tsai; Yi-Sheng Liou; Chen-Chieh Yang; Chao-Wen Hsueh; Wu-Hsien Kuo
Journal:  World J Hepatol       Date:  2015-06-08

7.  Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial.

Authors:  D Dimitroulopoulos; D Xinopoulos; K Tsamakidis; A Zisimopoulos; E Andriotis; D Panagiotakos; A Fotopoulou; C Chrysohoou; A Bazinis; D Daskalopoulou; E Paraskevas
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

8.  A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher.

Authors:  Usman Shah; Bert O'Neil; Jill Allen; Richard M Goldberg; Steven Bernard; Dominic Moore; Alan P Venook; Michael M Morse
Journal:  Gastrointest Cancer Res       Date:  2009-03

Review 9.  Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.

Authors:  Xi-Qing Ji; Xin-Jian Ruan; Hong Chen; Gang Chen; Shi-Yong Li; Bo Yu
Journal:  Med Sci Monit       Date:  2011-08

10.  Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells.

Authors:  Céline Kerros; Thibault Cavey; Brigitte Sola; Philippe Jauzac; Stéphane Allouche
Journal:  J Exp Clin Cancer Res       Date:  2009-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.